The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial
Abstract
The inflammatory reflex, in which vagus nerve signaling modulates cytokine production, is dysregulated in rheumatoid arthritis (RA). RESET-RA, a pivotal, double-blind, randomized, sham-controlled trial, evaluated a vagus nerve-targeted neuromodulation system for RA in 242 patients with inadequate response/intolerance to biological/targeted synthetic disease-modifying antirheumatic drugs. Patients were randomized to active or sham stimulation for 3 months, and then all received open-label stimulation with results reported to 12 months. The primary end point was 3-month American College of Rheumatology 20% (ACR20) response. ACR20 rates were higher with active simulation than with sham at 3 months (35.2% versus 24.2%, P = 0.0209), which further improved in open-label to 50.0% at 6 months and 52.8% at 12 months (all-completers). Adverse events occurred in a similar proportion of patients in both arms. Related serious adverse events (rate = 1.6%) were all perioperative, and resolved. Vagus nerve-mediated neuroimmune modulation for RA achieved its primary efficacy end point and produced durable clinical benefits with a favorable safety profile. ClinicalTrials.gov registration: NCT04539964 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tracey, K. J. (2009) · Nature Reviews Immunology · doi:10.1038/nri2566 · Cited by 1,154 · cited 1×
“Actively stimulating the vagus nerve can engage the inflammatory reflex, resulting in acetylcholine release and specific agonism of α7 nicotinic acetylcholine receptors on immune cells 6,7 .”
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
Schett, G., & Gravallese, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.153 · Cited by 947 · cited 1×
“In this higher erosive-risk phenotype, active stimulation attenuated the rate of erosion progression, a clinically relevant effect, given that progressive MRI-detectable erosions at 3 months predict radiographic progression at 12 months and subsequent functional decline 26,27 .”
Rethinking inflammation: neural circuits in the regulation of immunity
Olofsson, P. S., Rosas‐Ballina, M., Levine, Y. A., & Tracey, K. J. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01138.x · Cited by 393 · cited 1×
“This broad-spectrum immunomodulation retains cytokine network bioavailability, thereby allowing reduction and resolution of inflammation while maintaining competent immunosurveillance against foreign pathogens and precancerous cells 9–11 .”
Self-citationHeart rate variability in patients with rheumatoid arthritis
Evrengül, H., Dursunoglu, D., Cobankara, V., Polat, B., Seleci, D., Kabukçu, S., Kaftan, A., Semiz, E., & Kilic, M. (2004) · Rheumatology International · doi:10.1007/s00296-003-0357-5 · Cited by 159
Research works printed but not linked: 39
- Di Matteo, A., Bathon, J. M. & Emery, P. Rheumatoid arthritis. Lancet 402, 2019–2033 (2023). · DOI · Paper page
- Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 73, 924–939 (2021). · DOI · Paper page
- Baker, M. C., Nagy, D., Tamang, S., Horvath-Puho, E. & Sorensen, H. T. Vagotomy and the incidence of rheumatoid arthritis and osteoarthritis: a Danish register-based study. Arthritis Res. Ther. 27, 106 (2025). · DOI
- Koopman, F. A. et al. Autonomic dysfunction precedes development of rheumatoid arthritis: a prospective cohort study. eBioMedicine 6, 231–237 (2016). · DOI
- Tracey, K. J. The inflammatory reflex. Nature 420, 853–859 (2002). · DOI · Paper page
- Chavan, S. S., Pavlov, V. A. & Tracey, K. J. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity 46, 927–942 (2017). · DOI · Paper page
- Pavlov, V. A. & Tracey, K. J. Bioelectronic medicine: preclinical insights and clinical advances. Neuron 110, 3627–3644 (2022). · DOI
- Dalli, J., Colas, R. A., Arnardottir, H. & Serhan, C. N. Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution. Immunity 46, 92–105 (2017). · DOI · Paper page
- Genovese, M. C. et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatol. 2, e527–e538 (2020). · DOI · Paper page
- Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 113, 8284–8289 (2016). · DOI · Paper page
- Gaylis, N. B. et al. Neuroimmune modulation for drug-refractory rheumatoid arthritis: long-term safety and efficacy in patients enrolled in a pilot vagus nerve stimulation study. Rheumatol. Ther. 12, 1125–1136 (2025). · DOI
- Peterson, D. et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron. Med. 10, 8 (2024). · DOI
- Levine, Y. A., Faltys, M. & Chernoff, D. Harnessing the inflammatory reflex for the treatment of inflammation-mediated diseases. Cold Spring Harb. Perspect. Med. 10, a034330 (2020). · DOI
- Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727–735 (1995). · DOI · Paper page
- Ostergaard, M. et al. The OMERACT rheumatoid arthritis magnetic resonance imaging (MRI) scoring system: updated recommendations by the OMERACT MRI in arthritis working group. J. Rheumatol. 44, 1706–1712 (2017). · DOI · Paper page
- Hofman, Z. L. M. et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?. Rheumatology (Oxford) 64, 65–73 (2025). · DOI
- Kay, J. et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res. Ther. 16, R40 (2014).
- Genovese, M. C. et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391, 2513–2524 (2018). · DOI · Paper page
- Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451–460 (2013). · DOI · Paper page
- Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005). · DOI · Paper page
- Genovese, M. C. et al. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med. 374, 1243–1252 (2016). · DOI · Paper page
- Gandjbakhch, F. et al. Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity. J. Rheumatol. 41, 398–406 (2014). · DOI
- Conaghan, P. G. et al. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis Res. Ther. 21, 214 (2019). · DOI
- Bajayo, A. et al. Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc. Natl Acad. Sci. USA 109, 15455–15460 (2012). · DOI · Paper page
- Tamimi, A. et al. Could vagus nerve stimulation influence bone remodeling?. J. Musculoskelet. Neuronal Interact. 21, 255–262 (2021).
- Levine, Y. A. et al. Neurostimulation of the cholinergic anti-inflammatory pathway ameliorates disease in rat collagen-induced arthritis. PLoS ONE 9, e104530 (2014).
- Elefteriou, F. Impact of the autonomic nervous system on the skeleton. Physiol. Rev. 98, 1083–1112 (2018). · DOI · Paper page
- Serhan, C. N., de la Rosa, X. & Jouvene, C. Novel mediators and mechanisms in the resolution of infectious inflammation: evidence for vagus regulation. J. Intern. Med. 286, 240–258 (2019). · DOI
- Ali, M., Yang, F., Plachokova, A. S., Jansen, J. A. & Walboomers, X. F. Application of specialized pro-resolving mediators in periodontitis and peri-implantitis: a review. Eur. J. Oral. Sci. 129, e12759 (2021).
- Bassi, G. S. et al. Modulation of experimental arthritis by vagal sensory and central brain stimulation. Brain Behav. Immun. 64, 330–343 (2017). · DOI
- Rosch, G., Zaucke, F. & Jenei-Lanzl, Z. Autonomic nervous regulation of cellular processes during subchondral bone remodeling in osteoarthritis. Am. J. Physiol. Cell Physiol. 325, C365–C384 (2023). · DOI
- Frisell, T. et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann. Rheum. Dis. 82, 601–610 (2023). · DOI
- Toffa, D. H., Touma, L., El Meskine, T., Bouthillier, A. & Nguyen, D. K. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: a critical review. Seizure 83, 104–123 (2020). · DOI · Paper page
- Baker, M. C. et al. A randomized, double-blind, sham-controlled, clinical trial of auricular vagus nerve stimulation for the treatment of active rheumatoid arthritis. Arthritis Rheumatol. 75, 2107–2115 (2023). · DOI
- Munoz Laguna, J., Lee, H., Poltavskiy, E., Kim, J. & Bang, H. Participant’s treatment guesses and adverse events in back pain trials: Nocebo in action?. Clin. Trials 21, 759–762 (2024). · DOI
- Bang, H., Flaherty, S. P., Kolahi, J. & Park, J. Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol. Clin. Res. Regul. Aff. 27, 42–51 (2010). · DOI · Paper page
- D'Haens, G. et al. Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn’s disease patients: a prospective open-label study. J. Crohns Colitis 17, 1897–1909 (2023). · DOI
- Baker, J. F., Conaghan, P. G., Emery, P., Baker, D. G. & Ostergaard, M. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann. Rheum. Dis. 75, 1114–1119 (2016). · doi:10.1136/annrheumdis-2014-206934
- Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800–802 (1988). · DOI · Paper page
Cited by
Gan, D., Qin, L., & Xiao, G. (2026) · Research · doi:10.34133/research.1319 · Cited by 1
Metadata
- Authors
- Tesser, J. R. P., Crowley, A. R., Box, E. J., June, J. P., Wickersham, P. B., Valenzuela, G. J., Gaylis, N. B., Lam, G. K. W., Pacheco, L. A., Ridley, D. J., Pinto-Patarroyo, G. P., Novack, S. N., Churchill, M. A., Kohler, M., Lee, E. C., Pando, J. A., Parris, G. R., Peterson, J. R., Shah, T., Singhal, A. K., Vuong, V., Levine, Y. A., Evangelista, M. L., Derosier, A. A., Curtis, J. R., Richardson, R. M., & Chernoff, D.
- Venue
- Nature Medicine
- Published
- 2025-12-22
- Volume
- 32
- Issue
- 1
- Pages
- 369-378
- ISSN
- 1078-8956
- 1546-170X
- Cited by
- 44
- References
- 4
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Funders
- SetPoint Medical, Inc.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. https://app.cochat.ai/papers/10.1038/s41591-025-04114-7
- The paper
- Tesser, J. R. P., Crowley, A. R., Box, E. J., June, J. P., Wickersham, P. B., Valenzuela, G. J., Gaylis, N. B., Lam, G. K. W., Pacheco, L. A., Ridley, D. J., Pinto-Patarroyo, G. P., Novack, S. N., Churchill, M. A., Kohler, M., Lee, E. C., Pando, J. A., Parris, G. R., Peterson, J. R., Shah, T., . . . Chernoff, D. (2026). Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-025-04114-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.